Abstract
To the Editor: I read with interest the paper by Solomon et al1 in which the authors have combined the analysis results of 2 independent trials, Adenoma Prevention With Celecoxib (APC)2 and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP),3 in an attempt to estimate cardiovascular events (CVs) associated with celecoxib across 3 different dose regimens. I am concerned about the validity of their combined analysis and their conclusion that celecoxib at 200 or 400 mg twice daily (APC) or at 400 mg once daily (PreSAP) showed a nearly 2-fold increase in …
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call